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WHAT’S NEW IN OVARIAN 
CANCER 
Jessica L Kozuki, MSN, NP-C, CNS, AOCNP 





• Review trends in incidence and mortality in ovarian 
cancer
• Describe the role of hereditary and somatic genetic 
testing
• Discuss current patient evaluation recommendations 
for women presenting with ovarian cancer
• Discuss primary treatment options for a new diagnosis 
of ovarian cancer
• Discuss new therapies in recurrent disease 
CLINICAL PRESENTATION & EVALUATION
 Suspicious/palpable pelvic mass on abdominal/pelvic exam and/or ascites, abdominal 
distension
 Symptoms without source of malignancy
 bloating, pelvic/abdominal Pain, difficulty eating or early satiety, urinary changes
 Ultrasound (TVUS), and/or CT A/P.  PET/CT or MRI if indeterminate lesions. 
 CA 125 and potentially other markers
 Family History
 Refer to GYN Oncology for clinically suspicious lesions.  
 GI additionally in some cases
 Diagnosis by previous surgery or tissue biopsy often a source of referrals
OVARIAN CANCER IS RELATIVELY RARE 
COMPARED WITH OTHER CANCERS
a Age-adjusted data from 2011–2016. 
1. National Cancer Institute. SEER Cancer Stat Facts: Ovarian Cancer. http://seer.cancer.gov/statfacts/html/ovary.html.
Published April 2019. Accessed May 9, 2019. 2. American Cancer Society. Key Statistics for Ovarian Cancer. 
https://www.cancer.org/cancer/ovarian-cancer/about/key-statistics.html. Last revised January 8, 2019. Accessed January 9, 2019. 3.
American Cancer Society. Cancer Facts & Figures 2018. https://www.cancer.org/content/dam/
cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2018/cancer-facts-and-figures-2018.pdf. Published 
2018. Accessed May 09, 2019.
A woman’s lifetime risk of getting ovarian cancer is about 1 in 782
Prevalence in United States1
229,875
based on 2016 estimates
Incidence in United States1,2
2019 projected 
total new diagnoses




Proportion of all new cancer 
diagnoses in USA in 20181
Proportion of all US cancer 
diagnoses in women up to 20153
2.5%
EPIDEMIOLOGICAL TRENDS SHOW A DECLINE 
IN OVARIAN CANCER INCIDENCE AND MORTALITY
 Over the last decade, ovarian cancer incidence has declined 
by 1.5% on average each year, while mortality has declined by 
2.3% on average each year
National Cancer Institute. SEER Cancer Stat Facts: Ovarian Cancer. http://seer.cancer.gov/statfacts/html/ovary.html.
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Tumor confined to ovaries/fallopian tube(s)
• IA: Tumor limited to 1 ovary (capsule intact) or fallopian tube 
• IB: Tumor limited to both ovaries (capsule intact) or fallopian tubes
• IC: Tumor limited to 1 or both ovaries or fallopian tubes with surgical spill (IC1), capsule ruptured/tumor on ovarian 
or fallopian tube surface (IC2), or malignant cells in ascites or peritoneal washings (IC3)
78–93 99 98
II
Tumor involves 1 or both ovaries or fallopian tubes with pelvic extension (below pelvic brim) 
or primary peritoneal cancer
• IIA: Extension and/or implants on uterus and/or fallopian tubes and/or ovaries
• IIB: Extension to other pelvic intraperitoneal tissues
61–82 79 90
III
Tumor involves 1 or both ovaries or fallopian tubes, or primary peritoneal cancer, with confirmed 
spread to peritoneum outside the pelvis and/or metastasis to retroperitoneal LNs
• IIIA1: Positive retroperitoneal LNs only 
• IIIA2: Microscopic extrapelvic (above pelvic brim) peritoneal involvement with or without positive retroperitoneal 
LNs
• IIIB: Macroscopic peritoneal metastasis beyond pelvis up to 2 cm, with or without metastasis to retroperitoneal LNs
• IIIC: Macroscopic peritoneal metastasis beyond pelvis more than 2 cm, with or without metastasis to 
retroperitoneal LNs (includes extension of tumor to liver and spleen capsule without parenchymal involvement)
28–63 63 87
IV
Distant metastasis excluding peritoneal metastases
• IVA: Pleural effusion with positive cytology
• IVB: Parenchymal metastases and metastases to extra-abdominal organs (including inguinal LNs and LNs outside of 
the abdominal cavity)
19 36 64
FIGO OVARIAN CANCER STAGING
FIGO, International Federation of Gynecology and Obstetrics; LN, lymph node.
1. Prat J, et al. Int J Gynaecol Obstet. 2014;124(1):1-5. 2. American Cancer Society. Survival Rates for Ovarian Cancer, by Stage. 
https://www.cancer.org/cancer/ovarian-cancer/detection-diagnosis-staging/survival-rates.html. Last revised April 11, 2018. 
Accessed May 09, 2019.
PRIMARY TREATMENT
 Maximum Surgical Debulking
 Aim of surgery is to confirm diagnosis, define extent of disease spread (staging), and resect all 
visible tumor tissue
 Platinum Based Chemotherapy-cornerstone of adjuvant therapy
 Always consider clinical trial options 
Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer V.1.2019. © 
National Comprehensive Cancer Network, Inc. 2019. All rights reserved. Accessed May 09, 2019. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no 





Stage IA–IV Surgical Candidate 
(fertility not desired)
Bulky Stage III/IV or 
Poor Surgical Candidate











• Evaluation by GYN ONC
• Total abdominal hysterectomy 
(TAH)/BSO
• Comprehensive staging 
and debulking as needed
• Evaluation by GYN ONC
• Histologic confirmation 
(biopsy preferred)
• Consider neoadjuvant 
chemotherapy (category 1c) ±
interval debulking surgery with 
TAH/BSO
National Comprehensive Cancer Network® (NCCN ®) Recommendations for 
Primary Surgical Treatment Based on Clinical Stage
DIAGNOSIS BY PREVIOUS SURGERY. 
ROLE FOR ADDITIONAL SURGERY? 
 Uterus Intact
 Adnexa Intact
 Omentum not removed
 Documentation of staging incomplete
 Residual disease, potentially resectable
 Occult invasive carcinoma found at time of risk reducing surgery
 Incomplete lymph node dissection
 Resectable=Surgery 
Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Ovarian Cancer Including Fallopian 
Tube Cancer and Primary Peritoneal Cancer V.1.2019. © National Comprehensive Cancer Network, Inc. 2019. All rights reserved. Accessed May 
09, 2019. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind 
whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
PLATINUM BASED CHEMOTHERAPY CORNER STONE
 One of the platinum-based chemotherapy options recommended in the NCCN 
Guidelines as postoperative treatment for epithelial ovarian cancer is IV paclitaxel 175 
mg/m2 followed by carboplatin AUC 5–6 Day 1; repeat every 3 weeks






 Other less common side effects 
BIOLOGIC IMPORTANCE OF OVARIAN CANCER
 Ovarian cancer is characterized by complex cellular and molecular 
processes.
 Heterogeneous
 Histological subtypes impact prognosis
 The identification of molecular aberrations, such as BRCA1/2mutations 
and homologous recombination repair pathway deficiencies have 
shaped treatment strategies




GERMLINE VS. SOMATIC MUTATIONS
Germline Testing Somatic Testing
• Well-established 
technique, 
easy extraction of DNA
• Accurate and 
reproducible
• Prognostic and predictive 
value supported by robust 
data
• Assess risk of developing 
other cancers
• Clinically relevant for 
family members
• Will identify smaller 
number of patients who 
may benefit from 
treatment
• NGS will identify more 
patients 
who may benefit from 
treatment
• Can help patients 
understand potential 
extent of benefit
• Can serve as a triage 
for germline testing
NGS, next-generation sequencing.
Frey MK, et al. Gynecol Oncol Res Pract. 2017;4:4. 
Germline Mutations
-Inherited from parents and become incorporated 
into DNA of every cell in the body of offspring
Somatic Mutations
-Acquired alterations in DNA that occur after 
conception that can (but do not always) cause 
cancer or other diseases
FDA-APPROVED OPTIONS FOR FIRST LINE MAINTENANCE 
THERAPY
bid, twice daily; BRCA, breast cancer susceptibility gene; CR, complete response; FDA, US Food and Drug Administration; IV, 
intravenous; g, germline; L, line; mut, mutation; PR, partial response; q3w, every 3 weeks; 
s, somatic. 









Bevacizumab in combination 
with carboplatin and 
paclitaxel, followed by 
bevacizumab as a single 
agent for treatment of 
patients with stage III or IV 
epithelial ovarian, fallopian 
tube, or primary peritoneal 
cancer following initial 
surgical resection
No
15 mg/kg IV q3w in 
combination with 
carboplatin and 
paclitaxel for up to 6 
cycles, followed by 15 
mg/kg q3w as a single 
agent, for a total of up 





treatment of adult patients 
with deleterious or suspected 
deleterious gBRCAmut or 
sBRCAmut advanced 
epithelial ovarian, fallopian 
tube, or primary peritoneal 
cancer who are in CR or PR 









(two 150-mg tablets) 
bid
RECURRENT DISEASE 
 Follow-up/monitoring visits are suggested every 2–4 mo for 2 years, then 3–6 mo for 3 
years, then annually after 5 years
 Most advanced ovarian cancers will recur during or after first-line treatment. 
 Median progression-free survival decreases upon each subsequent recurrence. 
 Patients with ovarian cancer whose disease recurs at least 6 months after treatment 
completion are considered to be platinum- or chemotherapy-sensitive.
LANDMARK FDA APPROVALS IN OVARIAN 
CANCER THERAPY
a In combination with carboplatin and paclitaxel, followed by bevacizumab alone.
BRCA, breast cancer susceptibility gene; dMMR, deficient mismatch repair; FDA, US Food and Drug 
Administration; 
MSI-H, high microsatellite instability; mut, mutation.
1. Drugs@FDA: FDA Approved Drug Products. https://www.accessdata.fda.gov/scripts/cder/daf/. 

















































 Single-agent chemotherapy may result in response
 Double-agent chemotherapy resulted in similar response levels to single-
agent treatment, but with more toxicity
 Patients with germline or somatic BRCA mutations may also respond to 
PARP inhibitors
 Clinical activity has also been demonstrated in patients with HRD-positive 
disease
 Bevacizumab addition to chemotherapy improves response, PFS, and 
QoL, but does not improve OS
BRCA, breast cancer susceptibility gene; HRD, homologous recombination deficiency; OS, overall survival; PARP, poly ADP ribose polymerase; PFS, progression-
free survival; PROC, platinum-resistant ovarian cancer; QoL, quality of life; wt, wild-type.
1. Herzog TJ. Clin Cancer Res. 2004;10(22):7439-49. 2. Oronsky B, et al. Med Oncol. 2017;34(6):103.
3. Domchek SM, et al. Gynecol Oncol. 2016;140(2):199-203. 4. Konecny GE, et al. Presented at SGO Annual 
Meeting, 2017. Abstract 1. 5. Moore KN, et al. Presented at ASCO Annual Meeting, 2018. Abstract 5514. 
6. Pujade-Lauraine E, et al. J Clin Oncol. 2014;32(13):1302-8. 7. Stockler MR, et al. J Clin Oncol. 2014;32(13):1309-16
PARP INHIBITION SUMMARY
 PARP inhibition is synthetically lethal for tumors with homologous 
recombination deficiency
 Currently, 3 PARP inhibitors are approved for patients with ovarian cancer 
across multiple indications
 First Line maintenance therapy: Olaparib (BRCAmut)
 Second Line maintenance therapy regardless of biomarker status (ie, including 
BRCAwt and BRCAmut): Olaparib, rucaparib, niraparib
 Treatment therapy after multiple prior lines of chemotherapy: Olaparib (gBRCAmut) 
and rucaparib (BRCAmut)
 Hematological adverse reactions are commonly associated with PARP 
inhibitors.  Regular lab monitoring.  
 Ongoing clinical trials are examining the efficacy of PARP inhibition across 
various lines of therapy and treatment approaches, including 
combination regimens
 PARP inhibition has shown clinical efficacy in patients without HRD
BRCA, breast cancer susceptibility gene; g, germline; HRD, homologous recombination deficiency; L, line; mut, mutation; PARP, poly ADP 
ribose polymerase; wt, wild-type.
1. Konstantinopoulos PA, et al. Cancer Discov. 2015;5(11):1137-54. 2. Olaparib package insert. AstraZeneca Pharmaceuticals LP; 
December 2018. 3. Rucaparib package insert. Clovis Oncology, Inc; April 2018. 4. Niraparib package insert. TESARO, Inc; February 2019.
5. ClinicalTrials.gov: NCT02282020, NCT02446600, NCT02470585, NCT02477644, NCT02502266, NCT02655016, NCT02855944, NCT03106987, 
NCT03278717, NCT03402841, NCT03519230, NCT03522246, NCT03534453, NCT03598270, NT03602859, NCT03642132, NCT03705156, NCT03709316, 
NCT03737643, NCT03740165, NCT03806049. Accessed January 15-16, 2019. 
6. Mirza MR, et al. N Engl J Med. 2016;375(22):2154-64.
FURTHER OPTIONS
 Programmed Death Ligand 1 (PDL-1)
 Helps define the population most likely to benefit from immunotherapy
 Pembrolizumab (Ketruda)
 Microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR)
 Immune Mediated Side Effects 
 Clinical Trials
 New Trial Coming 
 GOG-2018
 Paclitaxel +/- for Recurrent Platinum-Resistant Ovarian Ca
 CL-OVA-PO1
 Autologous Dendritic Cells Loaded with Autologous Tumor Associated Antigens for Advanced Epithelial Ovarian 
Carcinomas
“ONCE YOU CHOOSE HOPE, ANYTHING’S POSSIBLE”
CHRISTOPHER REEVE
